Lat­est news on thumbs down for Nu­plazid; Amy­lyx’s first ALS ap­proval; Buy­out buzz for trou­bled biotechs; Cannes Li­ons pre­view; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

It’s one con­fer­ence af­ter the oth­er in June. Now that #BIO22 is be­hind us, we’re shift­ing gears to Zach Bren­nan’s up­com­ing events at #DIA22 and on-the-ground cov­er­age from Cannes Li­ons by Beth Sny­der Bu­lik and Nicole De­Feud­is. If you’re tak­ing a long week­end like us — we’re off Mon­day in ob­ser­vance of June­teenth — I hope it’s just what you need.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER